Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.74 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897009 | 0.92 | MAP3K5 (0.87) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3897012 | 0.92 | MAP3K5 (0.87) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL6792459 | 0.85 | MAP3K5 (0.84) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL6790880 | 0.85 | HIF1AN (0.74) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3905768 | 0.85 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3905770 | 0.85 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL6785810 | 0.85 | MAP3K5 (0.73) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL8290210 | 0.83 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL23433501 | 0.82 | HIF1AN (0.81) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL23433454 | 0.82 | HIF1AN (0.81) | MAP3K5HIF1ANMEN1KMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | claimed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | claimed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | claimed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MAP3K5 4055/4885HIF1AN 285/4885MEN1 3202/4885 |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MAP3K5 4055/4885HIF1AN 285/4885MEN1 3202/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MAP3K5 4055/4885HIF1AN 285/4885MEN1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.